Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00874250 · ClinicalTrials.gov registry record · NA

Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic

A NA study, sponsored by W.L.Gore & Associates.

Completed
Registry status
NA
Development phase
51
Enrollment target

NCT00874250 is a NA study that has completed, run by W.L.Gore & Associates. The registered enrollment target is 51 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00874250, a NA study, has completed, sponsored by W.L.Gore & Associates.

COMPLETED
Registry status
NA
Development phase
51 participants
Enrollment target

Study Summary

To assess the safety and efficacy of the GORE Conformable TAG® Thoracic Endoprosthesis in the primary treatment of aneurysm of the descending thoracic aorta (DTA) \> Primary Hypothesis: The proportion of subjects free from a major device event through 1 month post-treatment will not be significantly less than 0.95, which represents the proportion observed in previous clinical studies with the GORE TAG® Thoracic Endoprosthesis

Interventions

  • DEVICE GORE CTAG Device

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2009-06
Est. Completion 2017-01-06
Phase NA

Sponsor

W.L.Gore & Associates

53 total trials

What the Registry Record Tells You About NCT00874250

The ClinicalTrials.gov registry entry for NCT00874250 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which GORE CTAG Device is the first listed.

NCT00874250 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00874250 about?

NCT00874250 is a clinical study titled "Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic". To assess the safety and efficacy of the GORE Conformable TAG® Thoracic Endoprosthesis in the primary treatment of aneurysm of the descending thoracic aorta (DTA) \> Primary Hypothesis: The proportion of subjects free from a major device event through 1 month post-treatment will not be significantl...

What is the current status of trial NCT00874250?

This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2009-06. Estimated completion is 2017-01-06.

What interventions are being tested in trial NCT00874250?

The interventions under investigation include: GORE CTAG Device (DEVICE).

Who is sponsoring clinical trial NCT00874250?

This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.